Table 1 Demographics and clinical baseline characteristics
|  | Atorvastatin (n = 36)†| Placebo (n = 32)†|
|---|---|---|
Age, years | 40.4 (34.8,45.5) | 43.0 (38.1,52.0) |
Male sex, n (%) | 15 (41.7%) | 15 (46.9%) |
Smoking history (pack years) | 24 (14,34) | 21 (10,30) |
Duration of asthma symptoms, years | 24.0 (14.5,32.5) | 19.5 (12.5, 38.5) |
Atopic, n (%) | 18 (54.5%) | 21 (67.7%) |
Total IgE (IU/ml) | 82 (19,192) | 197 (76,517) |
Use of inhaled corticosteroid at screening, n (%) | 19 (52.8%) | 16 (50.0%) |
Equivalent beclometasone dose at screening, μg | 100 (0,400) | 200 (0,800) |
Use of LABA at screening, n (%) | 8 (22.2%) | 14 (43.8%) |
Pre-bronchodilator FEV1 % predicted | 84 (71,98) | 79 (65,92) |
FEV1 % reversibility | 11 (6,16) | 12 (8,19) |
Serum cotinine (ng/mL) | 85 (78,90) | 82 (79,94) |